Roberto de Franchis, MD; Gianmichele Meucci, MD; Maurizio Vecchi, MD; Maria Tatarella, MD; Massimo Colombo, MD; Ersilio Del Ninno, MD; Maria Grazia Rumi, MD; Maria Francesca Donato, MD; Guido Ronchi, MD
de Franchis R., Meucci G., Vecchi M., Tatarella M., Colombo M., Del Ninno E., Rumi M., Donato M., Ronchi G.; The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers. Ann Intern Med. 1993;118:191-194. doi: 10.7326/0003-4819-118-3-199302010-00006
Download citation file:
Published: Ann Intern Med. 1993;118(3):191-194.
To assess the long-term outcome in hepatitis B surface antigen (HBsAg) carriers who have normal liver function tests, focusing on survival and the development of severe liver disease and hepatocellular carcinoma.
Cohort study with a mean follow-up of 130 months.
Liver clinic of a referral center.
Ninety-two HBsAg-positive blood donors with normal liver function tests.
Histologic evaluation of liver specimens at baseline; clinical, biochemical, and serologic follow-up; and repeat liver biopsy if clinically indicated or after 10 years of follow-up.
At baseline, 69 subjects had normal histologic findings or only minor abnormalities, 18 had chronic persistent hepatitis, and 5 had mild chronic active hepatitis. Serum enzyme levels remained normal in 58 of 68 patients who had regular follow-up. Three patients had biochemical changes consistent with hepatitis B virus (HBV) infection; in one of these patients, a later histologic evaluation showed progression to chronic active hepatitis. One patient developed alcoholic cirrhosis. Six other patients had mild or transient transaminase elevations, with no evidence of HBV replication, hepatitis D virus infection, hepatitis C virus (HCV) infection, or histologic deterioration. Liver histologic findings also remained unchanged in 21 patients who showed no biochemical changes during 10 years of follow-up and consented to have repeated liver biopsy. Ten patients showed loss of HBsAg; 2 of these patients acquired antibody to hepatitis B surface antigen (anti-HBs). All patients who did not have regular follow-up, except 1, were interviewed by telephone during 1990: All denied having liver disease. No patients developed hepatocellular carcinoma.
Italian HBsAg carriers with initially normal liver function tests have an excellent prognosis: Delta superinfection is infrequent and the risk for developing hepatocellular carcinoma is low.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only